Novo Nordisk Shares Fall as Investors Doubt New Strategy and Pipeline Plans
Danish pharmaceutical giant Novo Nordisk announced plans to launch more than five potential blockbuster drugs by 2030 at its Capital Markets Day, but the update failed to reassure investors. The company's shares fell 8% following the event, compounding a two-year decline in value. Analysts from Barclays and Jefferies noted that the strategy lacked new disclosures or strategic resets needed to restore confidence. CEO Mike Doustdar acknowledged the need for Novo Nordisk to rebuild trust with investors through consistent financial and scientific results over time. The company is racing against its chief rival, Eli Lilly—whose shares have risen 58% in a year—to replenish its pipeline as semaglutide-based drugs like Ozempic and Wegovy face patent expiration in the early 2030s. While Doustdar emphasized diversification into areas such as cardiovascular and liver diseases, analysts remain skeptical about Novo's ability to move beyond obesity. The CEO also hinted at a potential role for mergers and acquisitions but did not rule out expanding within its core diabetes and weight-loss markets.
Topics: Investor Relations Pharmaceuticals Stock Performance Strategic Plans